The most recent trading session ended with Vertex Pharmaceuticals (VRTX) standing at $416.96 ... while the tech-heavy Nasdaq depreciated by 0.89%. Coming into today, shares of the drugmaker ...
VRTX insiders have traded $VRTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales. Here’s a ...
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...
Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the ...
The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $428, representing a +0.03% change from its previous close.
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with a substantial market capitalization of $110.13 billion, continues to ...
NEW YORK, NY / ACCESSWIRE / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
ISRG), and Vertex Pharmaceuticals (NASDAQ: VRTX) are unstoppable stocks to buy in 2025. David Jagielski (Eli Lilly): It may look as though Eli Lilly's stock has peaked given its recent slide ...
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $416.96, moving -1.72% from the previous trading session.
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.